RCM
CRXTW

Radcliffe Capital Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Radcliffe Capital Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-70,893
Closed -$371K – 1122
2021
Q3 		$371K Sell
70,893
-154,107
-68% -$116K 0.01% 851
2021
Q2 		$2.27M Hold
225,000
– – 0.07% 444
2021
Q1 		$2.27M Buy
+225,000
New +$180K 0.09% 390

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $19.4M AUM
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Radcliffe Capital Management's CRXTW Position: Q4 2021 in Review

Radcliffe Capital Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q4 2021, closing a stake of 70,893 shares — an estimated $371K sold.

Radcliffe Capital Management first reported a position in CRXTW in Q1 2021 and held it in 3 quarters. The position peaked at $2.27M in Q2 2021. 19 funds tracked by Wall St. Rank hold CRXTW as of Q4 2021.

  • Radcliffe Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q4 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 70,893 Clarus Therapeutics Holdings, Inc. Warrants shares in Q4 2021, an estimated $371K.
  • Radcliffe Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q1 2021 and held it in 3 quarters.
  • Radcliffe Capital Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $2.27M in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q4 2021.

Based on Radcliffe Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.